What is the role of prophylactic antibiotics in preventing meningococcal infection in eculizumab-treated patients?

Mar 7, 2025 ... Soliris, whose active substance is eculizumab, is a first‐in‐class biologic therapy designed to inhibit a key protein in the complement cascade— ... Aug 10, 2021 ... This review presents a discussion on the therapeutic efficacy and tolerability of eculizumab in patients with MG and a summary on relevant pharmacological data. Indicated for paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Doses 1-4: 600 mg IV qWeek for first 4 weeks, followed by Dose 5: 900 mg IV 1 week ... Jun 2, 2024 ... Both eculizumab and efgartigimod provide more treatment benefits to patients with generalized myasthenia gravis compared with conventional immunosuppressive ... Jan 7, 2022 ... Soliris® (eculizumab) is the first medication to be approved by the Australian Therapeutic Goods Administration (TGA) for the treatment of an MS ... 600mg weekly for the first 4 weeks, followed by 900mg for the fifth dose 1 week later, then 900mg every 2 weeks thereafter. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and to evaluate the effectiveness of Soliris ... Soliris is not expected to affect the aplastic component of anaemia in patients with PNH. Meningococcal Infection. Due to its mechanism of action, the use of ... As anti-C5 therapy like eculizumab is the only treatment for patients with aHUS, optimizing treatment is indispensable. The drug label states that a trough ... Jul 14, 2017 ... What is already known about this topic? Eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is associated with a ...